Delving into the Latest Updates on Paclitaxel/Cisplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TP

Target

DNA x Tubulin

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors), Tubulin inhibitors, DNA alkylating agents

+ [2]

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Locally Advanced Head and Neck Squamous Cell Carcinoma

Originator Organization

Tianjin Cancer Institute

Active Organization-

Inactive Organization

Tianjin Cancer Institute

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS Registry33069-62-4

View All Structures (2)

This is a single-center, single-arm, phase II study, aiming to preliminarily explore the efficacy and safety of JS004 combined with toripalimab and chemotherapy for perioperative treatment of locally advanced thoracic esophageal squamous cell carcinoma that is resectable. The plan is to enroll 20 patients with locally advanced resectable thoracic esophageal cancer. In the neoadjuvant treatment phase, patients will receive JS004 + toripalimab + chemotherapy (paclitaxel + cisplatin) for 2 cycles. This will be followed by the surgical phase: surgery will be performed 3-8 weeks after the last dose of neoadjuvant treatment. In the postoperative maintenance treatment phase, maintenance treatment will start 4 weeks ± 7 days after surgery, but no later than 10 weeks after surgery. For patients with R0 resection confirmed by postoperative pathology, they will receive maintenance treatment with JS004 + toripalimab for up to 15 cycles. For patients with non-R0 resection, they will receive maintenance treatment with JS004 + toripalimab combined with standard radiation or chemotherapy (selected by the investigator based on esophageal cancer guidelines). During the study, the maximum number of cycles of JS004 combined with toripalimab is 17 cycles (approximately 1 year).

Start Date30 Sep 2024

Sponsor / Collaborator

Henan Provincial Peoples Hospital

NCT06444009

/ RecruitingPhase 2IIT

Neoadjuvant Immunotherapy in Combination With Chemotherapy in Resectable Head and Neck Cancer：A Randomized, Phase II Study

A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection.
This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.

Start Date01 Jul 2024

Sponsor / Collaborator

West China Hospital

NCT05520619

/ Active, not recruitingPhase 2IIT

Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)

Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in EC. The aim of this study was to evaluate whether the efficacy of tislelizumab (an anti-PD-1 antibody) plus induction chemotherapy followed by concurrent chemoradiotherapy would achieve a ≥71% 1-year progression-free survival rate, surpassing the historical 56% rate (NCT02403531) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

Start Date15 Sep 2022

Sponsor / Collaborator

Sun Yat-Sen University

[+2]

100 Clinical Results associated with Paclitaxel/Cisplatin

Login to view more data

100 Translational Medicine associated with Paclitaxel/Cisplatin

Login to view more data

100 Patents (Medical) associated with Paclitaxel/Cisplatin

Login to view more data

2,088

Literatures (Medical) associated with Paclitaxel/Cisplatin

01 Mar 2025·Pesticide Biochemistry and Physiology

A comparative study of the controllable release and insecticidal efficacy for two typical carrier methods on diamide insecticide delivery system

Article

Author: Huang, Yucong ; Yang, Huiying ; Liu, Xingyu ; Liu, Bingrui ; Li, Yahui ; Li, Shaochen

Using nano/microcarriers of pesticides in sustainable pest management represents a promising strategy for enhancing pesticide efficiency while mitigating environmental harm. The reported pesticide loading methods include one-step self-assembly encapsulation and two-step absorption loading, but the controllable release and insecticidal efficacy of these two methods have been infrequently evaluated. Herein, the typical diamide insecticide cyantraniliprole (CTP) was employed as the model pesticide. A hydrogen bond-driven one-step self-assembly method and a chemical deposition method were utilized to fabricate highly dispersed polylactic acid (PLA) microspheres and calcium carbonate (CaCO₃) microspheres. The resulting CTP-loaded PLA microspheres (CTP-PLA MS) and CaCO₃ microspheres (CTP-CaCO₃ MS) both exhibited high adhesion, resistance to rain erosion, and insecticidal activity under laboratory conditions. However, the functional CTP-PLA MS demonstrated superior sustained pesticide release performance, higher pesticide loading capacity, and less application amount than that of CTP-CaCO₃ MS. At the same time, the acute toxicity of CTP-PLA MS exhibited slightly reduced acute toxicity to honeybees (Apis mellifera), signifying enhanced biocompatibility. Finally, the CTP-PLA MS maintained superior insecticidal efficacy than the normal CTP in controlling O. nubilalis at a low concentration. The present study represents a promising pesticide carrier as a highly efficient, eco-friendly agent for sustained management of O. nubilalis.

01 Mar 2025·Reproductive Toxicology

Hormonal mechanism and pathogenetic therapy of citalopram-induced infertility in female rats

Article

Author: Suleyman, Halis ; Gumusburun, Neset ; Bulut, Seval ; Mendil, Ali Sefa ; Suleyman, Bahadir ; Bakan, Nuri ; Delibasi, Ilhan Bahri ; Yilmaz, Betul Kalkan ; Altuner, Durdu ; Mammadov, Renad

Citalopram is a selective serotonin reuptake inhibitor (SSRI) and has been associated with reproductive dysfunction in women. In this study, the effects of citalopram on reproductive health in female rats were investigated. Albino Wistar rats was divided into six groups (each group/n=12): healthy (HG), citalopram (CTP), cabergoline (CBR), metyrapone (MTP), cabergoline+citalopram (CBR+CTP), and metyrapone+citalopram (MTP+CTP). Initially, cabergoline 0.1mg/kg and metyrapone 50mg/kg were administered orally. A dose of 10mg/kg of citalopram was given orally one hour later. For 30 days, the treatment protocol was applied once a day. Then, blood samples were taken from the tail veins of six rats from each group for prolactin and corticosterone analyses and ovaries were removed after euthanasia. The ovaries were examined for oxidants and antioxidants and histopathologically. During two months, the remaining animals were kept with male rats. The rats that did not deliver during this period were considered infertile. In terms of oxidants and antioxidants, there was no significant difference between the groups (p>0.05). In half of the female rats, citalopram caused infertility, increased levels of prolactin and corticosterone, and damaged the ovaries histopathologically (p<0.05). Cabergoline suppressed the elevation of prolactin by citalopram (p<0.001) but did not prevent infertility. In contrast, metyrapone significantly prevented the citalopram-induced increase in corticosterone, infertility, and tissue damage induced by citalopram (p<0.05). According to the results of our study, the preventive effect of drugs that suppress excessive corticosterone on citalopram-induced infertility in rats may be encouraging for further clinical studies.

01 Nov 2024·3 Biotech

Pharmacokinetic predictions of ROS-mediated targets and genotoxin combinations via multiple ligand simultaneous docking and ROS evaluation in vitro using HepG2 cell lines

Article

Author: Sri Snehaa, C. P. ; Issac, Praveen Kumar ; Sri Snehaa, C P ; Rajaguru, Palanisamy ; Pugalenthi, Velan

Although combination therapy is known for its high efficacy, reduced side effects and drug resistance, toxicity remains a major drawback. Some of the genes are likely to induce hepatotoxicity through ROS-mediated mechanisms when a drug is metabolized alone or in combination in the liver. To address this, we have developed a scientific approach to predict the toxicity of different genotoxin combinations and validate their interactions with various targets. The current study is an extensive study of our previous set of in vivo rat liver microarray data processed using R studio for their functional analysis. About five combinations of genotoxins such as CPT/ETP, CPT/CPL, ETP/CPL, CP/CPT and EES/CP along with their differential gene expression targeting Chemical carcinogenesis-ROS are chosen for this study. We aim to examine the binding affinity of different genotoxin combinations using in silico multiple ligand simultaneous docking (MLSD) and are then bio-evaluated for cytotoxicity in vitro using human hepatocellular carcinoma cell lines (HepG2) with the MTT assay. As a result, dose-response cytotoxicity with its strength of interactions and a significant variance in ROS levels in the treated cells is observed compared to their IC₅₀ values. Out of 5 combinations such as CPT/CPL, ETP/CPL and EES/CP are found not only to be significantly cytotoxic but also induce oxidative stress specifically above their IC₅₀ values with good and moderate binding interactions ensuring their toxicity. On the contrary, the safe combinations are found to be CTP/ETP and CP/CPT possibly with no and tolerable adverse effects standing as preliminary information for researchers in drug design and development.

100 Deals associated with Paclitaxel/Cisplatin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 2	China	Tianjin Cancer Institute	07 Nov 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ASIA2023	Not Applicable	Locally Advanced Head and Neck Squamous Cell Carcinoma Neoadjuvant	21	Pembrolizumab plus TP	(wagjhvnhnd) = xrdkadycgg hmvvdmdsyg (ngwohsjxnb ) View more	-	02 Dec 2023
ESMO_ASIA2023	Not Applicable		21	Pembrolizumab plus DP	(wagjhvnhnd) = jqyalngufh hmvvdmdsyg (ngwohsjxnb ) View more	-	02 Dec 2023
ASCO2016	Phase 2	Recurrent Cervical Cancer	65	Cisplatin-Paclitaxel regimen	(jtstlkkblr) = jmtbdxptzk puysgtznka (tkqdgjohdt ) View more	Positive	20 May 2016
ASCO2015	Not Applicable	Locally Advanced Head and Neck Squamous Cell Carcinoma	-	Paclitaxel 80 mg/m2 plus cisplatin 75 mg/m2	(ctfunhjtlx) = ntxmsuxbbx wmxiynbmnk (vkpvnexfhs ) View more	-	20 May 2015
ASCO2014	Not Applicable	Squamous Cell Carcinoma of the Penis	41	Paclitaxel plus cisplatin	(fgcgzkhmif) = mjqakmznrf jqatqexllx (puvoxlegcm ) View more	-	20 May 2014
ASCO_GU2014	Not Applicable	Squamous Cell Carcinoma of the Penis Adjuvant \| Neoadjuvant	47	Paclitaxel plus cisplatin and 5-fluorouracil (T-PF)	(ppuszipddm) = moxhemnvag mynwknskpn (rcgdlflqtf )	-	01 Feb 2014
WCLC2013	Not Applicable	Advanced Lung Squamous Cell Carcinoma	32	Docetaxel/cisplatin chemotherapy and thoracic radiotherapy	(ebamtldtwg) = gsyyopjsda zyjkfdidil (guvqfxlscn, 63 - 97) View more	-	29 Oct 2013
ASCO2013	Not Applicable	Advanced Esophageal Squamous Cell Carcinoma	133	Paclitaxel plus cisplatin	(hhuvarsygt) = dylydedmdy pptwtxheuk (rgwpofewev, 5.68 - 8.32) View more	-	20 May 2013
ASCO2013	Not Applicable	Locally Advanced Cervical Carcinoma	47	Cisplatin, paclitaxel, and capecitabine	dypwtmkgyx(zhiphhsndn) = xdkiobxyfz mfrishvdvg (wjruznggjo ) View more	-	20 May 2013
ASCO2011	Not Applicable	Metastatic Gastric Carcinoma First line \| Second line	75	Paclitaxel, cisplatin, and fluorouracil (PCF)	(vafzfqikyw) = scymsxmmzd vydiulwyls (jizjkbzldi ) View more	-	20 May 2011
ASCO2011	Phase 2	Non-Small Cell Lung Cancer	-	Paclitaxel plus cisplatin	(pjmawodwys) = ifhlsflruo jnuuponkxf (ssrizhqtkg ) View more	Positive	20 May 2011
ASCO2011	Phase 2	Non-Small Cell Lung Cancer	-	Paclitaxel plus cisplatin with Cadi-05	(pjmawodwys) = avghdttjrd jnuuponkxf (ssrizhqtkg ) View more	Positive	20 May 2011